L
Lever Bio
Expertise in drug development and global partnerships to advance innovative therapeutics
About Lever Bio
Lever Bio is a strategic initiative backed by Claris Ventures and Exor Ventures, focusing on advancing drug development through collaboration with top-tier researchers. The company operates at the intersection of science and business, aiming to translate groundbreaking discoveries into impactful therapeutics. Lever Bio prioritizes projects with validated targets in high medical need areas, particularly those originating from Italian research centers or Italian researchers abroad. By providing an initial budget to support partnered programs, Lever Bio seeks to progress these initiatives towards preclinical candidates. The business model revolves around forming strategic partnerships and leveraging a global business development network to drive innovation in drug development. Lever Bio's commitment to resource optimization and synergy creation positions it as a premier partner for researchers exploring new therapeutic opportunities.
Source: Dealroom company dataAt a glance
- Founded
- 2024
- Headquarters
- Turin, Italy
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Claris Ventures
Ora Global
Italian Angels for Growth
Investors' club
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lever Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lever Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.